The company said that entry into the Chinese medical devices market is an opportunity, given the market's size.
The European Medicines Agency (EMEA) and US Food and Drug Administration (FDA) have already approved both the EndoPat and WatchPat.
Itamar Medical's share price rose 6.6% by mid-afternoon to NIS 2.10, giving a market cap of NIS 263 million.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments